• BetterLife Pharma priced a public offering of up to 555,000,000 common shares at CDN$ 0.25 for up to US$ 100 million.
• Investors can instead buy pre-funded warrants at CDN$ 0.25, exercisable for one common share at $0.00001.
• Bloom Burton Securities, Haywood Securities to act as agents on a commercially reasonable efforts basis; closing targeted around Sept. 15, 2026.
• 15% over-allotment option for 30 days; agents to receive a 7% cash commission, broker warrants equal to 7% of securities.
• Proceeds earmarked for clinical development in cluster headache, migraine, broader working capital.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BetterLife Pharma Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202608280800NEWSFILECNPR____20260828_311933_1) on August 28, 2026, and is solely responsible for the information contained therein.